FERTINEX
LOE Approachingurofollitropin
NDASUBCUTANEOUSINJECTABLE
Approved
Sep 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FERTINEX (urofollitropin) is a urinary-derived follicle-stimulating hormone (FSH) injectable used to stimulate ovarian follicle development in women with infertility, anovulation, and subfertility. Administered subcutaneously, it mimics the natural FSH hormone to promote egg maturation and ovulation in assisted reproductive technology (ART) cycles.
LOE Approaching
Product faces moderate competitive pressure (30/100) with approaching loss of exclusivity, signaling a contracting team focused on market defense rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program
Started Oct 2013
263 enrolled
Infertility
Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females
Started Oct 2013
215 enrolled
Anovulation
Career Relevance
Roles on FERTINEX are primarily defensive in nature, focused on preserving market share and managing the transition through LOE rather than driving growth. Career advancement on this product is limited; high performers typically transition to growth-stage products or into strategic portfolio roles.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.